ClinicalTrials.gg
CompletedNCT00013871Updated Nov 1, 2021

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

An interventional study of Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed and Measles-Mumps-Rubella Vaccine (Live) in HIV Infections, Hepatitis B and Measles, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 40 sites in 2 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2021-11-01.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
300
Ages
2 Years to 18 Years
Sex
All
01

Study summary

The purpose of this study is to determine if 2 doses of Pneumococcal Conjugate Vaccine (PCV) followed by 1 dose of Pneumococcal Polysaccharide Vaccine (PPV) in HIV-infected children on anti-HIV therapy is helpful and safe in fighting pneumococcal infections in this group of children. This study will also look at the protection provided by childhood vaccination against measles, pertussis, and hepatitis B virus.

Pneumococcal infections are the most common AIDS-related infection in HIV-infected children. PCV may help reduce the chances of HIV-infected children getting pneumococcal infections. This study will look at whether pneumococcal vaccines are safe and effective in HIV-infected children receiving HAART. It will look at whether HIV-infected children are protected by childhood vaccines received previously and if more doses are safe and improve protection.

Read the detailed description

Infection by Streptococcus pneumoniae is the most frequent opportunistic infection observed in HIV-infected children. PCVs are immunogenic and efficacious in normal children and offer hope of reducing pneumococcal infections in HIV-infected children. The degree to which children on HAART are protected by prior immunizations and are responsive to new immunizations is still largely undefined. This study is designed to answer whether PCV immunizations are safe and effective. The immune responses to prior immunizations and responsiveness to booster doses of vaccines against measles, pertussis, and hepatitis B virus of children on HAART will also be examined. Answers to these questions will determine whether these children are likely to be protected against these clinically relevant pathogens and whether they should routinely receive booster doses of these vaccines after a period of HAART.

Patients are stratified on the basis of CD4 percentage and age. Patients that previously received a primary hepatitis B vaccine (HBV) series receive an HBV immunization at entry. Other vaccinations may be given (based on age and/or CD4 cell measurement, and immunization status) for PCV at entry and 2 months, and measles-mumps-rubella (MMR) vaccine and PPV at 4 months. Some patients may be administered DTaP at a 6-month visit on the basis of age, previous immunization history, and negative tetanus antibody status. Follow-up visits are done at 8, 12, and 24 months. Blood samples are collected at all clinic visits for assessment of HIV RNA, immune responses against pneumococcus, measles, pertussis, and hepatitis B virus, as well as for laboratory evaluations.

02

Conditions studied

  • HIV Infections
  • Hepatitis B
  • Measles
  • Pneumococcal Infections
  • Pertussis

Keywords

  • Measles-Mumps-Rubella Vaccine
  • Antibodies, Viral
  • Hepatitis B Vaccines
  • Immunization, Secondary
  • Pneumococcal Vaccines
  • Antiretroviral Therapy, Highly Active
  • Diphtheria-Tetanus-acellular Pertussis Vaccines
03

In context

HIV Infections

4,734 studies on the registry are indexed under HIV Infections; 244 are open to participants now.

This study's enrollment of 300 is above the median of 80 across 3,489 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,446 studies on the registry; 179 are open to participants now.

Of its 405 completed or terminated interventional studies of FDA-regulated products, 302 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be eligible for this study if they:

  • Are 2 to 18 years of age.
  • Are -infected.
  • Have a viral load (amount of HIV in the blood) under 60,000 copies/ml within 30 days of study entry.
  • Have been on their current anti-HIV drugs for at least 3 months.
  • Have received 4 or more doses of a pertussis vaccine.
  • Have received 1 or more doses of measles vaccine unless a CD4 percent or CD4 number ruled out taking the vaccine. (This reflects a change in the CD4 requirement.)
  • Expect to be able to complete all study injections and follow-up.
  • Have a negative pregnancy test if able to have children and use effective methods of .
  • Have parent or guardian's consent if under 18 years of age.
  • Have received an approved vaccine series. Not required for study entry, but children who have received this vaccine will be studied.
  • (This study was changed to allow patients who became HIV infected after birth, have a viral load between 30,000 and 60,000 copies/ml, and who have been on their current anti-HIV drugs for 3 to 6 months.)

Exclusion criteria

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Had a certain CD4 level before beginning anti- drugs and at screening.
  • Have received any killed vaccine within 4 weeks, or any within 6 weeks, of entering the study.
  • Have received pneumococcal vaccines or had a reaction to PPV.
  • Have had an allergic reaction to any measles or vaccines, or to other routine childhood immunizations if 13 years of age or less.
  • Have any other condition that would make receiving study vaccines inadvisable.
  • Are currently on medications that affect the immune system, except for G-CSF and erythropoietin. This includes the equivalent to more than 1 mg/kg/day of prednisone in the 2 weeks preceding study screening. Nonsteroidal anti-inflammatory agents and inhaled are not excluded.
  • Have received certain blood products within the previous 6 months.
  • Have other diseases of the immune system.
  • Have had cancer within 3 months of study screening or are being treated or have been treated for cancer within 3 months of study entry.
  • Are pregnant.
  • Have any other disease or previous surgery that would interfere with study treatment.
  • Are likely to have bleeding disorders.
  • Show certain side effects to vaccines at screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Enrollment
300 participants

Interventions

06

Study locations

40 sites
  • UAB, Dept. of Ped., Div. of Infectious Diseases
    Birmingham, Alabama 35233, United States
  • Long Beach Memorial Med. Ctr., Miller Children's Hosp.
    Long Beach, California 90801, United States
  • Usc La Nichd Crs
    Los Angeles, California 90033, United States
  • Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab.
    Oakland, California 94609, United States
  • UCSD Mother-Child-Adolescent Program CRS
    San Diego, California 92103, United States
  • UCSF Pediatric AIDS CRS
    San Francisco, California 94143, United States
  • Univ. of Colorado Denver NICHD CRS
    Aurora, Colorado 80218, United States
  • Connecticut Children's Med. Ctr.
    Hartford, Connecticut, United States
  • Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease
    New Haven, Connecticut 06504, United States
  • Children's National Med. Ctr. Washington DC NICHD CRS
    Washington, District of Columbia, United States
  • South Florida CDTC Ft Lauderdale NICHD CRS
    Fort Lauderdale, Florida, United States
  • Univ. of Florida College of Medicine-Dept of Peds, Div. of Immunology, Infectious Diseases & Allergy
    Gainesville, Florida 32610, United States
  • Univ. of Florida Jacksonville NICHD CRS
    Jacksonville, Florida 32209, United States
  • Univ. of Miami Ped. Perinatal HIV/AIDS CRS
    Miami, Florida 33161, United States
  • Columbus Regional HealthCare System, The Med. Ctr.
    Columbus, Georgia 31901, United States
  • Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease
    Chicago, Illinois 60614, United States
  • Chicago Children's CRS
    Chicago, Illinois 60637, United States
  • Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology
    Baltimore, Maryland 21201, United States
  • Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases
    Baltimore, Maryland 21287, United States
  • HMS - Children's Hosp. Boston, Div. of Infectious Diseases
    Boston, Massachusetts 02115, United States
  • BMC, Div. of Ped Infectious Diseases
    Boston, Massachusetts 02118, United States
  • Baystate Health, Baystate Med. Ctr.
    Springfield, Massachusetts 01199, United States
  • WNE Maternal Pediatric Adolescent AIDS CRS
    Worcester, Massachusetts 01655, United States
  • Rutgers - New Jersey Medical School CRS
    Newark, New Jersey 07103, United States
  • Bronx-Lebanon Hosp. IMPAACT CRS
    Bronx, New York 10457, United States
  • Montefiore Med. Ctr. - AECOM
    Bronx, New York 19461, United States
  • SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS
    Brooklyn, New York 11203, United States
  • Schneider Children's Hosp., Div. of Infectious Diseases
    New Hyde Park, New York 11040, United States
  • Nyu Ny Nichd Crs
    New York, New York 10016, United States
  • Columbia IMPAACT CRS
    New York, New York 10032, United States
  • Harlem Hosp. Ctr. NY NICHD CRS
    New York, New York 10037, United States
  • Cornell Univ., Div. of Ped. Infectious Diseases & Immunology
    New York, New York, United States
  • Metropolitan Hosp. Ctr.
    New York, New York, United States
  • St. Luke's-Roosevelt Hosp. Ctr.
    New York, New York, United States
  • Strong Memorial Hospital Rochester NY NICHD CRS
    Rochester, New York 14642, United States
  • SUNY Stony Brook NICHD CRS
    Stony Brook, New York 11794, United States
  • St. Christopher's Hosp. for Children
    Philadelphia, Pennsylvania, United States
  • Texas Children's Hosp. CRS
    Houston, Texas 77030, United States
  • San Juan City Hosp. PR NICHD CRS
    San Juan, Puerto Rico
  • Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS
    San Juan, Puerto Rico
07

References and documents

Publications

  • Abzug MJ, Qin M, Levin MJ, Fenton T, Beeler JA, Bellini WJ, Audet S, Sowers SB, Borkowsky W, Nachman SA, Pelton SI, Rosenblatt HM; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams. Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis. 2012 Aug 15;206(4):512-22. doi: 10.1093/infdis/jis386. Epub 2012 Jun 12. PubMed 22693229 ↗
  • Abzug MJ, Warshaw M, Rosenblatt HM, Levin MJ, Nachman SA, Pelton SI, Borkowsky W, Fenton T; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis. 2009 Sep 15;200(6):935-46. doi: 10.1086/605448. PubMed 19663708 ↗
  • Abzug MJ, Song LY, Fenton T, Nachman SA, Levin MJ, Rosenblatt HM, Pelton SI, Borkowsky W, Edwards KM, Peters J; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 Protocol Team. Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics. 2007 Nov;120(5):e1190-202. doi: 10.1542/peds.2007-0729. Epub 2007 Oct 15. PubMed 17938165 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00013871
Responsible party
Sponsor
First posted
Aug 31, 2001
Completion
Nov 2004
Last update
Nov 1, 2021

Study contacts

Mark Abzug
study chair
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion